Recursion Pharmaceuticals Price Performance News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recursion pharmaceuticals price performance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recursion Pharmaceuticals Price Performance Today - Breaking & Trending Today

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.5%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price fell 5.5% during trading on Wednesday . The stock traded as low as $8.45 and last traded at $8.50. 1,189,638 shares changed hands during trading, a decline of 81% from the average session volume of 6,164,144 shares. The stock had previously closed at $8.99. Wall […] ....

Christopher Gibson , Blake Borgeson , Investment Management , Recursion Pharmaceuticals , Hedge Funds Weigh In On Recursion Pharmaceuticals , Vanguard Group Inc , Sumitomo Mitsui Trust Holdings Inc , Needham Company , Recursion Pharmaceuticals Inc , Recursion Pharmaceuticals Price Performance , News Ratings For Recursion Pharmaceuticals Daily , Insider Activity At Recursion Pharmaceuticals , Mubadala Investment Co , Get Free Report , Director Blake Borgeson , Sumitomo Mitsui Trust Holdings , Mitsui Trust Holdings , Recursion Pharmaceuticals Daily ,

Recursion Pharmaceuticals (NASDAQ:RXRX) Receives Buy Rating from Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX) Receives Buy Rating from Needham & Company LLC
modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.

Tina Marriott , Michael Secora , Analyst Recommendations For Recursion Pharmaceuticals , Recursion Pharmaceuticals Price Performance , Institutional Investors Weigh In On Recursion Pharmaceuticals , Recursion Pharmaceuticals , Needham Company , Recursion Pharmaceuticals Inc , Vanguard Group Inc , News Ratings For Recursion Pharmaceuticals Daily , Kingsview Wealth Management , Securities Exchange Commission , Interchange Capital Partners , Free Report , Get Free Report , Exchange Commission , Welath Management , Wealth Management , Capital Partners , Recursion Pharmaceuticals Daily ,

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.9% After Insider Selling

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.9% After Insider Selling
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Tina Marriott Larson , Christopher Gibson , Recursion Pharmaceuticals Price Performance , Mubadala Investment Co , Recursion Pharmaceuticals , Blackrock Inc , Recursion Pharmaceuticals Company Profile , Securities Exchange Commission , Hedge Funds Weigh In On Recursion Pharmaceuticals , News Ratings For Recursion Pharmaceuticals Daily , Vanguard Group Inc , Needham Company , Investment Management , Recursion Pharmaceuticals Inc , Get Free Report , Marriott Larson , Exchange Commission , Recursion Pharmaceuticals Daily ,

Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Increased to $17.00 by Analysts at Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its target price upped by Needham & Company LLC from $15.00 to $17.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently issued reports on RXRX. TD Cowen initiated coverage on Recursion Pharmaceuticals […] ....

Christopher Gibson , Tina Marriott , Investment Management , Needham Company , Recursion Pharmaceuticals Inc , Vanguard Group Inc , Insider Transactions At Recursion Pharmaceuticals , News Ratings For Recursion Pharmaceuticals Daily , Recursion Pharmaceuticals Company Profile , Sumitomo Mitsui Trust Holdings Inc , Jpmorgan Chase Co , Blackrock Inc , Recursion Pharmaceuticals , Recursion Pharmaceuticals Price Performance , Hedge Funds Weigh In On Recursion Pharmaceuticals , Free Report , Sumitomo Mitsui Trust Holdings , Mitsui Trust Holdings , Get Free Report , Recursion Pharmaceuticals Daily , Nasdaq Rxrx , Boost Price Target , Needham Company Llc ,

Baillie Gifford & Co. Trims Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Baillie Gifford & Co. lowered its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 2.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,551,409 shares of the company’s stock after selling 546,221 shares during the quarter. Baillie Gifford & […] ....

Blake Borgeson , Christopher Gibson , Securities Exchange Commission , Recursion Pharmaceuticals Price Performance , Needham Company , Recursion Pharmaceuticals Inc , Recursion Pharmaceuticals , Quarter For Recursion Pharmaceuticals , Norges Bank , Blackrock Inc , Jpmorgan Chase Co , News Ratings For Recursion Pharmaceuticals Daily , Sumitomo Mitsui Trust Holdings Inc , Investment Management , Baillie Gifford Co , Baillie Gifford , Free Report , Mitsui Trust Holdings , Street Corp , Director Blake Borgeson , Visit Holdingschannel , Recursion Pharmaceuticals Daily , Nasdaq Rxrx , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,